Bridgewater Associates LP Sells 31,869 Shares of Phreesia, Inc. (NYSE:PHR)

Bridgewater Associates LP cut its stake in shares of Phreesia, Inc. (NYSE:PHR) by 51.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,445 shares of the company’s stock after selling 31,869 shares during the quarter. Bridgewater Associates LP owned approximately 0.05% of Phreesia worth $694,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Deerfield Management Company L.P. Series C acquired a new stake in shares of Phreesia during the 2nd quarter worth about $4,078,000. Champlain Investment Partners LLC increased its holdings in shares of Phreesia by 4.1% during the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock worth $57,062,000 after buying an additional 97,847 shares in the last quarter. Sei Investments Co. raised its stake in shares of Phreesia by 135.3% in the second quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock valued at $3,505,000 after acquiring an additional 95,058 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Phreesia by 56.3% in the 2nd quarter. Squarepoint Ops LLC now owns 250,396 shares of the company’s stock worth $5,308,000 after acquiring an additional 90,215 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Phreesia during the 3rd quarter worth approximately $954,000. 92.10% of the stock is owned by institutional investors.

Phreesia Price Performance

PHR opened at $21.10 on Tuesday. The company has a fifty day moving average price of $20.43 and a two-hundred day moving average price of $21.84. The firm has a market capitalization of $1.22 billion, a PE ratio of -11.72 and a beta of 0.94. Phreesia, Inc. has a 52 week low of $14.55 and a 52 week high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million during the quarter, compared to analysts’ expectations of $101.76 million. As a group, analysts anticipate that Phreesia, Inc. will post -1.23 earnings per share for the current year.

Insider Buying and Selling at Phreesia

In related news, insider Yvonne Hui sold 2,791 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.92, for a total value of $58,387.72. Following the completion of the transaction, the insider now directly owns 27,228 shares in the company, valued at approximately $569,609.76. The trade was a 9.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Balaji Gandhi sold 3,502 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total transaction of $81,421.50. Following the sale, the chief financial officer now owns 98,578 shares in the company, valued at $2,291,938.50. This trade represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,997 shares of company stock valued at $667,943. Corporate insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

PHR has been the subject of several research analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. JPMorgan Chase & Co. upped their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, September 9th. Truist Financial raised their price objective on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, September 6th. Robert W. Baird boosted their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Thursday, September 5th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Phreesia presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.42.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.